PAVmed's Best News Landed in a Subsidiary It No Longer Controls
A tale of two balance sheets
PAVmed reported on 13 November with its stock down roughly 71% over ninety trading days, having fallen from a $6.10 close on 15 July to something near $1.60 — a 73% drawdown into the print. The headline in the release, and in Lishan Aklog's opening, was unambiguously good: Lucid Diagnostics, in which PAVmed holds roughly 15% of the common and about 25% of the voting interest, is now getting paid by Medicare for EsoGuard. “Lucid began submitting claims through its Texas laboratory in late September and has been paid consistently since October at the full Medicare rate.” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-13 The CEO called it "critical and transformational."
Read the mechanics closely, though, and the milestone is narrower than the word "coverage" implies. What Lucid has is a consistent paid-claims pattern — what Aklog describes as coverage "through claim-by-claim adjudication" — not a formal coverage determination. That distinction has been the whole ballgame for over a year: the company's own keyword history shows Medicare coverage surfacing as a top theme in 2025Q2 and 2025Q3, and a 2026Q3 keyword literally references warrants "exercised post LCD publication" — a local coverage determination that never arrived. The reimbursement question has been answered, but answered by the cash register rather than by the contractor's rulebook. October was a record month for test volume; that is the number that matters now.
The covenant nobody led with
Here is where the story inverts. Lucid's good news does not flow to PAVmed as revenue or cash — it flows through an equity-method stake marked to market. Lucid closed the quarter at $0.75, down from $1.07, and Dennis McGrath was explicit that the resulting $10 million writedown is "the single largest item in our third quarter P&L." GAAP net loss widened to $13 million from $6 million a year ago; the non-GAAP loss of $1.2 million actually improved sequentially. The gap between those two numbers is almost entirely noncash mark-to-market noise.
The genuinely new disclosure this quarter is buried in the balance-sheet remarks, and it produced two keywords that were absent from prior quarters: collateral account as additional security and collateral coverage covenant. The $15 million senior secured note — 15% coupon, interest-only, maturing February 2029 — is collateralised against the market value of the Lucid shares. When Lucid fell, the covenant broke.
With the decline in Lucid's share price during the quarter, we did not satisfy that collateral coverage covenant as of September 30. The noteholder has agreed to waive that covenant through the date of our SEC filing, and we continue to work constructively with the noteholder as we have consistently in the past on covenants going forward.
That is the hinge of the whole report. PAVmed's single best fundamental news item this quarter is an asset whose price decline simultaneously tripped a covenant on the parent's debt. Covenant is now a top-of-mind theme where it previously was not, and it changes the character of the equity from "sum of the parts" to "financing story."
The liquidity arithmetic is unforgiving. Cash at 30 September was $8.9 million, of which $5.3 million is restricted — $5 million of it sitting in that collateral account. Effective net cash was already deeply negative at the last filed quarter, and the cash-runway calculation implied barely a quarter of breathing room:
Effective net cash of -$11 million and a cash runway of 1.4 quartersManagement's answer is instruments, not operations: $2.8 million raised in Q3 (the maximum allowable under the old facility), a fresh $9.4 million at-the-market programme with A.G.P. that McGrath says is "presently fully available," $30 million potentially from Series D warrants that are currently out of the money, and $2.5 million of Veris warrants callable on FDA clearance. Underlying burn was $2.8 million against non-GAAP operating expenses of $5.6 million—offset by what management presents as a pro forma $3 million-plus per quarter of Veris revenue plus Lucid management fees.
De Novo: the keyword management is trying to retire
The most striking keyword artefact of this quarter is that De Novo ranks as the company's second-biggest theme — and the entire thrust of the call is that PAVmed may not need it. For PortIO, the implantable intraosseous port, the original FDA engagement landed on the longer, costlier De Novo pathway. After a first-in-human study in Colombia and a "successful" initial FDA call in late October, the company now thinks a 510(k) is achievable by narrowing the intended use: “our strong preference would be to be able to do so through the 510(k) pathway, which would be shorter and less capital — less capital requirements and potentially might not even need additional human data” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-13.
This is not a new idea, and that matters. In August, Ed Woo asked the same question and Aklog said “there's no certainty yet, but that we may be able to pursue a 510(k) pathway with existing short-term intraosseous devices as a predicate” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-08-14. Two quarters of hope now have a January pre-submission meeting attached — progress, but the same hope. The De Novo keyword ranks high because De Novo is the thing being argued about, not because it is the plan.
Pre cancer and molecular test tell the Octeris story: the Duke-licensed optical platform is now positioned not merely as a better mousetrap but as a category killer for the molecular risk-stratification tests that sit between a positive EsoGuard and a confirmatory endoscopy. The next-generation probe is complete, the presubmission package goes in this month, and UNC enrolment is targeted for January. It is also, by Aklog's own prior admission, "several years away."
The registry that quietly moved a quarter
On Veris, the tone was upbeat and the numbers were qualitative. Monthly enrolment at Ohio State nearly doubled July to September and the rollout now covers most departments at the James. But compare the calendar. In May, Jeremy Pearlman asked about "a target enrollment by the end of this year of 1,000 patients" and got “We're not going to put numbers. But yes, it's trending and on target.” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-05-15 On this call the same target acquired a date: “The target for that was to do so by the end of the first quarter of next year, and we're on pace to do that” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-13. Whether that is a slip or a restatement of the original anniversary date, the effect is the same — the landmark for the Cancer Center registry has drifted past year-end.
The other-centre question got the same answer for the third straight quarter. Asked about interest from other large implantable monitoring customers, Aklog said: “There have been some contacts. There have been some discussions with a handful, but we have not been aggressively pursuing it” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-11-13 — consistent with May's “We're unlikely to pull the trigger on another major engagement until we're in a position to raise additional capital” — Lishan Aklog, Chairman and Chief Executive Officer · 2026-05-15. Consistency is admirable; it is also the sound of a commercial ramp frozen at one site for want of funding.
The bottom line. PAVmed is a $10.7 million market cap whose most valuable asset just became more valuable in a way the parent's P&L cannot yet show, while its own balance sheet required a covenant waiver to get through the filing. The Medicare catalyst is real and sits inside a cluster of reimbursement-driven small-cap medtech stories across this week's tape — the Kidney Care National Plan chatter at dialysis names is the same species of policy-tailwind trade. But PAVmed's version of it comes with a 15% coupon, restricted cash, and an ATM. Watch the next Lucid print and the January PortIO meeting; the covenant waiver is the thing that decides whether shareholders get to see either.